Second-guessing cancer treatments, a boyish side to soy and more in this week's news
Two-drug therapy for lung cancer
Patients age 70 or older with lung cancer should get two drugs rather than the currently recommended single-drug therapy, scientists in France report online August 9 in the Lancet. The researchers randomly assigned 448 lung cancer patients, median age 77, to get either two standard chemotherapies or one. The double-treatment group had a median survival time of 10.3 months, and 45 percent lived longer than one year. The single-drug group survived a median of 6.2 months and only 25 percent survived a year. Despite observing more side effects in the double-therapy patients, the researchers argue that the longer survival times suggest that current treatment guidelines be reconsidered. —Nathan Seppa
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.